Experts Propose New Psoriasis Biologic Tapering
A new international consensus provides a standardized 2-step approach for patients who have well-controlled psoriasis.
Updated on Oct. 20, 2026 in Diabetes
Live Poll
Should doctors prioritize expert consensus guidelines when clinical trial data is limited or absent?
An international panel of 62 dermatologists established a new 2-step algorithm for tapering psoriasis biologics in 2026. This consensus offers a standardized approach for patients who have achieved well-controlled skin conditions.
Why it matters
Managing biologic dosage in psoriasis has historically lacked standardized practice, making it difficult for clinicians to safely reduce treatments for patients in remission. This new guidance provides a structured framework to minimize medication exposure while maintaining disease control.
This expert consensus, published in 2026, utilized a modified eDelphi process with 62 dermatologists from six continents to reach agreement on 11 statements. Because the findings rely on expert opinion rather than prospective clinical trials, the efficacy of the 2-step approach is preliminary.
The players
Journal of the European Academy of Dermatology and Venereology
A peer-reviewed publication that reports on medical research concerning skin health and dermatological treatments.
The details
The newly established algorithm provides a 2-step strategy for tapering biologics, specifically targeting adalimumab, etanercept, and ustekinumab. Dermatologists also agreed the methodology holds potential applicability for interleukin-17 and interleukin-23 inhibitors. The consensus was finalized through three rounds of voting on a 9-point Likert scale to determine the most reliable protocols for dose reduction.
Timeline
The consensus study was published in the Journal of the European Academy of Dermatology and Venereology in 2026.
Health Landscape
This study uses the eDelphi process to establish clinical standards in a field where long-term management protocols often rely on individual clinician judgment. It represents an initial attempt to harmonize international practice for biologic tapering in stable psoriasis patients.
If you are currently managing psoriasis with biologics, this 2-step tapering approach is a topic worth discussing with your dermatologist during your next visit. Always consult your physician before considering any adjustments to your established medication dosage or treatment regimen.
The takeaway
Standardizing how biologic medications are reduced may help patients maintain results while using the lowest effective dose. Always keep your dermatologist informed of your health status to ensure any changes to your care plan are safe and appropriate for your specific clinical history.
Further reading
Learn more about the latest research and standard of care in the Diabetes section.
Source note: This article includes information reported by Ajmc.
Live Poll
Should doctors prioritize expert consensus guidelines when clinical trial data is limited or absent?
